The White House says Trump’s recent executive order is aimed at restoring trust in vaccines. It will do the opposite, writes an epidemiologist.
Matthew Herper covers medical innovation — both its promise and its perils. History tells us that President Trump’s executive order calling for the measles, mumps, and rubella vaccine to be split into ...
On Monday, Trump signed an order that sought to unilaterally change the federal government’s approach to vaccinating children: recommending fewer shots, spreading them over longer periods, and doing ...
President Donald Trump’s administration said that Medicaid will stop paying for gender-affirming surgeries and hormone treatments for transgender minors and the state Children’s Health Insurance ...
Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.
John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of ...
As institutional review boards face pressure from companies and ethicists, North Star Review Board offers a nonprofit model as more independent.
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...
Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...
The Trump administration, which had recently avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results